Zach Malchano serves as the President and Chief of Research and Development at Cognito Therapeutics. Zach joined as the first employee of Cognito, and under Zach’s leadership, Cognito has translated preclinical findings into multiple phase 2 clinical studies of gamma sensory stimulation in Alzheimer’s disease. Zach enjoys working at the intersection of medicine and engineering. In his current role, he oversees upstream research on new clinical indications for gamma sensory stimulation and advanced technologies to enable and optimize therapy delivery. Over the past 20 years, Zach has led development of innovative therapies in multiple medical specialties. He is a founder and early-stage team member at multiple venture backed medical technology companies. He is an inventor on more than 35 issued patents and an author on more than a dozen research articles. Zach is an affiliate faculty member at Harvard Medical School where he has helped to develop the HealthTech Fellowship program. Outside of Cognito, Zach enjoys outdoor activities such as running, cycling, and climbing, and woodworking; however, his main focus is on his family including two young children. Zach received his S.B. in Electrical Engineering from MIT and his M.Eng. in Biomedical Engineering from the Harvard-MIT Division of Health Sciences and Technology (HST), and he was a Biodesign Innovation Fellow at Stanford University.